NEW YORK (GenomeWeb News) – Correlogic Systems this week said that it has fulfilled European Union regulatory requirements to CE Mark its OvaCheck test for epithelial ovarian cancer. The test is a multiplex assay that measures the relative ratios of eight proteins. The Germantwon, Md.-based firm said that it is currently in discussions with potential partners for distribution of OvaCheck in Europe.
NanoString Technologies has launched an early-access program for its nCounter Custom Copy Number Variation Assays for highly multiplexed, direct-digital detection, and counting of CNVs in a single reaction. The firm expects to commercially launch the CNV assays later this year.
Covance this week said that it has opened a new, 20,000-square-foot biorepository to hold its plasma, serum, whole-blood, DNA, PBMC, and tissue samples. The new facility is adjacent to Covance's Biomarker Center of Excellence in Greenfield, Ind.
Becton Dickinson has signed agreements this week to sell certain assets of its BD Medical segment, including its ophthalmic systems unit and the surgical blades, critical care, and extended dwell catheter product platforms of its medical surgical systems unit. Private equity firm RoundTable Healthcare Partners and two of its portfolio companies, Argon Medical Devices and Aspen Surgical Products, are buying the BD assets for an undisclosed sum. BD said the businesses would bring in estimated revenues of $200 million for fiscal-year 2010.
Lab901 has received IS O9001:2008 accreditation for manufacturing quality covering its ScreenTape System for automated gel electrophoresis.